Bortezomib Abolishes Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Resistance via a p21-Dependent Mechanism in Human Bladder and Prostate Cancer Cells

A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry

1991 • 4,682 citations

Identification and characterization of a new member of the TNF family that induces apoptosis

1995 • 2,890 citations

Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

1999 • 2,494 citations

Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules

1994 • 2,480 citations

Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis

1994 • 2,450 citations

Safety and antitumor activity of recombinant soluble Apo2 ligand

1999 • 2,215 citations

Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor.

1995 • 2,142 citations

The Receptor for the Cytotoxic Ligand TRAIL

1997 • 1,755 citations

Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors

1997 • 1,694 citations

An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL

1997 • 1,506 citations

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1999 • 1,447 citations

Apoptosis control by death and decoy receptors

1999 • 1,296 citations

Apo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5

2000 • 968 citations

NF-κB as a Therapeutic Target in Multiple Myeloma

2002 • 906 citations

TRAIL and apoptosis induction by TNF-family death receptors

2003 • 843 citations

FADD/MORT1 and Caspase-8 Are Recruited to TRAIL Receptors 1 and 2 and Are Essential for Apoptosis Mediated by TRAIL Receptor 2

2000 • 792 citations

Back to the Future with Ubiquitin

2004 • 676 citations

TRAIL receptor-2 signals apoptosis through FADD and caspase-8

2000 • 651 citations

NF-κB as a therapeutic target in cancer

2002 • 550 citations

Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.

2001 • 481 citations

Targeting death receptors in cancer with Apo2L/TRAIL

2004 • 367 citations

Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice.

1996 • 365 citations

Characterization of two receptors for TRAIL¹

1997 • 293 citations

Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells

2004 • 269 citations

Oncogenes and cell death

1994 • 266 citations

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

2001 • 263 citations

Proteasome Inhibition: a New Strategy in Cancer Treatment

2000 • 252 citations

Sensitization for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by the Chemopreventive Agent Resveratrol

2004 • 247 citations

The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP

2003 • 235 citations

Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.

2003 • 232 citations

Inhibition of Nuclear Factor κB Activation Attenuates Apoptosis Resistance in Lymphoid Cells

1998 • 225 citations

Chemosensitization of Pancreatic Cancer by Inhibition of the 26S Proteasome

2001 • 215 citations

Mcl-1 Mediates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Human Cholangiocarcinoma Cells

2004 • 213 citations

Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

2000 • 212 citations

Proteasome inhibition in cancer: Development of PS-341

2001 • 178 citations

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

2003 • 172 citations

Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts.

2002 • 169 citations

Isolation and Characterization of Metastatic Variants from Human Transitional Cell Carcinoma Passaged by Orthotopic Implantation in Athymic Nude Mice

1995 • 168 citations

Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts.

2003 • 164 citations

Cell Cycle Regulation in the G1 Phase: A Promising Target for the Development of New Chemotherapeutic Anticancer Agents

2001 • 156 citations

Phosphorylation of FADD/ MORT1 at Serine 194 and Association with a 70-kDa Cell Cycle-Regulated Protein Kinase

2000 • 152 citations

Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy

2003 • 149 citations

New insights into proteasome function: from archaebacteria to drug development

1995 • 136 citations

Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP

2004 • 135 citations

The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts

2004 • 134 citations

Flavopiridol Induces p53 via Initial Inhibition of Mdm2 and p21 and, Independently of p53, Sensitizes Apoptosis-Reluctant Cells to Tumor Necrosis Factor

2004 • 121 citations

Flavopiridol, An Inhibitor of Transcription: Implications, Problems and Solutions

2004 • 113 citations

Inhibition of NF-κB Activity Enhances TRAIL Mediated Apoptosis in Breast Cancer Cell Lines

2000 • 107 citations

Enhanced Sensitivity of G1 Arrested Human Cancer Cells Suggests a Novel Therapeutic Strategy Using a Combination of Simvastatin and TRAIL

2002 • 91 citations

Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines.

2003 • 90 citations

The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo

2004 • 80 citations

Phosphorylation of FADD is critical for sensitivity to anticancer drug-induced apoptosis

2004 • 69 citations

Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation

2004 • 64 citations

Cell Cycle Effects by C-FADD Depend on Its C-terminal Phosphorylation Site

2003 • 49 citations